Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 1, 2008, Pages 160-166

  Goetz, M P ^a   Kamal, A ^a   Ames, M M ^a,b  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

ALLELE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CATALYSIS; CHEMOPROPHYLAXIS; DRUG BLOOD LEVEL; DRUG LABELING; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVITY; FOOD AND DRUG ADMINISTRATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; PHARMACOGENOMICS; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; BIOTRANSFORMATION; BREAST NEOPLASMS; CELL PROLIFERATION; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GENOTYPE; HUMANS; PATIENT SELECTION; PHARMACOGENETICS; PHENOTYPE; TAMOXIFEN; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 37549006389     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100367     Document Type: Review

References (55)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358, 1389-1399 (2001).
2. Easton, D.F., Bishop, D.T., Ford, D. & Crockford, G.P. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The breast cancer linkage consortium. Am. J. Hum. Genet. 52, 678-701 (1993).
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy hormonal therapy for early breast cancer on recurrence 15-year survival: an overview of the randomised trials. Lancet 365, 1687-1717 (2005).
4. Fisher, B. et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst. 97, 1652-1662 (2005).
5. Fisher, B. et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J. Clin. Oncol. 20, 4141-4149 (2002).
6. Colleoni, M. et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J. Clin. Oncol. 24, 1332-1341 (2006).
7. Howell, A. et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365, 60-62 (2005).
8. Thurlimann, B. et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med. 353, 2747-2757 (2005).
9. Coombes, R.C. et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N. Engl. J. Med. 350, 1081-1092 (2004).
10. Jakesz, R. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366, 455-462 (2005).
11. Goss, P.E. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97, 1262-1271 (2005).
12. Coates, A.S. et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J. Clin. Oncol. 25, 486-492 (2007).
13. Jonat, W. et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol. 7, 991-996 (2006).
14. Coombes, R.C. et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 369, 559-570 (2007).
15. Winer, E.P. et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J. Clin. Oncol. 23, 619-629 (2005).
16. Ingle, J.N. et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin. Cancer Res. 5, 1642-1649 (1999).
17. Bratherton, D.G. et al. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 versus 20mg bd. Br. J. Cancer 50, 199-205 (1984).
18. MacCallum, J. et al. Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours. Br. J. Cancer 82, 1629-1635 (2000).
19. Stearns, V. et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J. Natl. Cancer Inst. 95, 1758-1764 (2003).
20. Johnson, M.D. et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat. 85, 151-159 (2004).
21. Buck, M.R., Coller, J.K., Murdter, T.E., Eichelbaum, M. & Knabbe, C. TGFb2 and TbRII are valid molecular biomarkers for the antiproliferative effects of tamoxifen and tamoxifen metabolites in breast cancer cells. Breast Cancer Res. Treat. (2007) (in press).
22. Lonning, P.E., Lien, E.A., Lundgren, S. & Kvinnsland, S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin. Pharmacokinet. 22, 327-358 (1992).
23. Crewe, H.K., Ellis, S.W., Lennard, M.S. & Tucker, G.T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem. Pharmacol. 53, 171-178 (1997).
24. Desta, Z., Ward, B.A., Soukhova, N.V. & Flockhart, D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. (2004).
25. Crewe, H.K., Notley, L.M., Wunsch, R.M., Lennard, M.S. & Gillam, E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30, 869-874 (2002).
26. Lee, K.H., Ward, B.A., Desta, Z., Flockhart, D.A. & Jones, D.R. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 791, 245-253 (2003).
27. Lien, E.A., Solheim, E. & Ueland, P.M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51, 4837-4844 (1991).
28. Jin, Y. et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl. Cancer Inst. 97, 30-39 (2005).
29. Stearns, V., Beebe, K.L., Iyengar, M. & Dube, E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289, 2827-2834 (2003).
30. Borges, S. et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin. Pharmacol. Ther. 80, 61-74 (2006).
31. Jordan, V.C., Collins, M.M., Rowsby, L. & Prestwich, G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J. Endocrinol. 75, 305-316 (1977).
32. Jordan, V.C. Metabolites of tamoxifen in animals and man: identification, pharmacology and significance. Breast Cancer Res. Treat. 2, 123-138 (1982).
33. Borgna, J.L. & Rochefort, H. Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem. 256, 859-868 (1981).
34. Robertson, D.W., Katzenellenbogen, J.A., Long, D.J., Rorke, E.A. & Katzenellenbogen, B.S. Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifen. J. Steroid Biochem. 16, 1-13 (1982).
35. Lien, E.A., Solheim, E., Lea, O.A., Lundgren, S., Kvinnsland, S. & Ueland, P.M. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res. 49, 2175-2183 (1989).
36. Lien, E.A., Anker, G., Lonning, P.E., Solheim, E. & Ueland, P.M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res. 50, 5851-5857 (1990).
37. Lim, Y.C., Desta, Z., Flockhart, D.A. & Skaar, T.C. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 55, 471-478 (2005).
38. Lim, Y.C. et al. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells. J. Pharmacol. Exp. Ther. 318, 503-512 (2006).
39. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
40. Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G. & Fuselli, S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17, 93-101 (2007).
41. Rodriguez-Antona, C. & Ingelman-Sundberg, M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 25, 1679-1691 (2006).
42. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F. & Ingelman-Sundberg, M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278, 441-446 (1996).
43. Goetz, M.P. et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
44. Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295 (1997).
45. Loprinzi, C.L. et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356, 2059-2063 (2000).
46. Loprinzi, C.L. et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 20, 1578-1583 (2002).
47. Kimmick, G.G., Lovato, J., McQuellon, R., Robinson, E. & Muss, H.B. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J. 12, 114-122 (2006).
48. Barton, D.L. et al. Pilot evaluation of citalopram for the relief of hot flashes. J. Support. Oncol. 1, 47-51 (2003).
49. Goetz, M.P. et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
50. Schroth, W. et al. Breast cancer treatment outcome with adjuvant tamoxifen in relation to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. (in press).
51. Nowell, S. et al. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J. Natl. Cancer Inst. 94, 1635-1640 (2002).
52. Wegman, P. et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res. 7, R284-R290 (2005).
53. Nowell, S.A. et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res. Treat. 91, 249-258 (2005).
54. Wegman, P., Elingarami, S., Carstensen, J., Stal, O., Nordenskjold, B. & Wingren, S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res. 9, R7 (2007).
55. Bonanni, B. et al. Polymorphism in the CYP2D6 tamoxifen- metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J. Clin. Oncol. 24, 3708-3709; author reply 3709 (2006).